References
- Loftsson T, Brewster ME. (1996). Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci, 85:1017–1025.
- Szejtli J, Szente L. (2005). Elimination of bitter, disgusting tastes of drugs and foods by cyclodextrins. Eur J Pharm Biopharm, 61:115–125.
- Uekama K, Hirayama F, Irie T. (1998). Cyclodextrin Drug Carrier Systems. Chem Rev, 98:2045–2076.
- Brewster ME, Loftsson T. (2007). Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev, 59:645–666.
- Del Valle MEM. (2003). Cyclodextrins and their uses: a review. Process Biochem, 39:1033–1046.
- Hedges AR. (1998). Industrial Applications of Cyclodextrins. Chem Rev, 98:2035–2044.
- Valentino JS, Rajewski AR. (1997). Cyclodextrins: Their future in drug formulation and delivery. Pharm Res Dordr, 14:556–567.
- Rassing RM. (1994). Chewing gum as a drug delivery system. Adv Drug Deliver Rev, 13:89–121.
- Hirayama F, Uekama K. (1999). Cyclodextrin-based controlled drug release system. Adv Drug Deliv Rev, 36:125–141.
- Stojanov M, Wimmer R, Larsen KL. (2011). Study of the inclusion complexes formed between cetirizine and a-, b-, and g-cyclodextrin and evaluation on their taste-masking properties. J Pharm Sci, 100:3177–3185.
- Cramer F, Saenger W, Spatz H.-Ch. (1967). Inclusion compounds. XIX. The formation of inclusion compounds of α-cyclodextrin in aqueous solutions. Thermodynamics and kinetics. J Am Chem Soc, 89:14–20.
- Skidgel RA, Erdos EG. (2005). Hystamine, bradykinin and their antagonists. In: Brunton LL., et al. ed Goodman and Gilman’s The Pharmacological Basis of Therapeutics – 11th ed. New York: The McGraw-Hill companies, 629–651.
- Andersen C, Lao ML. (2010). Stable medicated chewing gum comprising cyclodextrin inclusion complex. Fertin Pharma AS. EP2178521 (A1).
- Jacobsen J, Bjerregaard S, Pedersen M. (1999). Cyclodextrin inclusion complexes of antimycotics intended to act in the oral cavity–drug supersaturation, toxicity on TR146 cells and release from a delivery system. Eur J Pharm Biopharm, 48:217–224.
- Testa ES. (1996). Medicated chewing gum and a process for preparation thereof. Avant-Garde Technologies & Products S.A. US005866179A.
- Yoshii H. (2007). Release kinetics of (-)-menthol from chewing gum. J Incl Phenom Macro, 57:591–596.
- Andersen RB, Nissen V. (2008). Compressed chewing gum tablet. Gumlink AS. EP1967234 (A1).
- Kvist C, Andersson SB, Fors S, Wennergren B, Berglund J. (1999). Apparatus for studying in vitro drug release from medicated chewing gums. Int J Pharm, 189:57–65.
- Morjaria Y, Irwin WJ, Barnett PX, Chan RS, Conway BR. (2004). In vitro release of nicotine from chewing gum formulations. Dissol Technol, 12–15.
- European Directorate for the Quality of Medicines & HealthCare. (2011). The European Pharmacopoeia. 7th Ed. Strasbourg: Council of Europe.
- Mikkelsen R. (2004). Method for producing compressed chewing gum tablets. WO2004/098305.
- Andersen C, Thorengaard B. (2010). Chewing gum granules for compressed chewing gum. Gumlink AS. EP2162016 (A1).
- Christensen PHE, Mikkelsen R. (2009). Compressed chewing gum tablets comprising at least gum granules. Gumlink AS. EP2022336 (A1).
- Cavallari C, Albertini B, González-Rodríguez ML, Rodriguez L, Abertini B. (2002). Improved dissolution behaviour of steam-granulated piroxicam. Eur J Pharm Biopharm, 54:65–73.
- Rawata S, Jain KS. (2004). Solubility enhancement of celecoxib using β-cyclodextrin inclusion complexes. Eur J Pharm Biopharm, 57:263–267.
- Riekes MK, Monika Piazzon Tagliari, Andrea Granada, Gislaine Kuminek, Marcos Antonio Segatto Silva, Hellen Karine Stulzer, et al. (2010). Enhanced solubility and dissolution rate of amiodarone by complexation with β-cyclodextrin through different methods. Materials Science and Engineering C, 30, 1008–1013.
- Pagliara A, Testa B, Carrupt PA, Jolliet P, Morin C, Morin D et al. (1998). Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist. J Med Chem, 41:853–863.